These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37296589)

  • 41. Alzheimer's Dementia: The Emerging Role of Positron Emission Tomography.
    Tripathi SM; Murray AD
    Neuroscientist; 2022 Oct; 28(5):507-519. PubMed ID: 33660556
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
    Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
    ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship between astrocyte reactivity, using novel
    Livingston NR; Calsolaro V; Hinz R; Nowell J; Raza S; Gentleman S; Tyacke RJ; Myers J; Venkataraman AV; Perneczky R; Gunn RN; Rabiner EA; Parker CA; Murphy PS; Wren PB; Nutt DJ; Matthews PM; Edison P
    Mol Psychiatry; 2022 Apr; 27(4):2019-2029. PubMed ID: 35125495
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.
    Bonomi CG; Assogna M; Di Donna MG; Bernocchi F; De Lucia V; Nuccetelli M; Fiorelli D; Loizzo S; Mercuri NB; Koch G; Martorana A; Motta C
    J Alzheimers Dis; 2023; 92(4):1385-1397. PubMed ID: 36911936
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo [18F]THK-5351 imaging detected reactive astrogliosis in argyrophilic grain disease with comorbid pathology: A clinicopathological study.
    Kobayashi R; Nakamura T; Naganuma F; Harada R; Morioka D; Kanoto M; Furumoto S; Kudo Y; Kabasawa T; Otani K; Futakuchi M; Kawakatsu S; Okamura N
    J Neuropathol Exp Neurol; 2023 Apr; 82(5):427-437. PubMed ID: 36882045
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The difference in gliosis induced by β-amyloid and Tau treatments in astrocyte cultures derived from senescence accelerated and normal mouse strains.
    Lü L; Mak YT; Fang M; Yew DT
    Biogerontology; 2009 Dec; 10(6):695-710. PubMed ID: 19221889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [
    Sanabria Bohórquez S; Marik J; Ogasawara A; Tinianow JN; Gill HS; Barret O; Tamagnan G; Alagille D; Ayalon G; Manser P; Bengtsson T; Ward M; Williams SP; Kerchner GA; Seibyl JP; Marek K; Weimer RM
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2077-2089. PubMed ID: 31254035
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
    Gordon BA; Blazey TM; Christensen J; Dincer A; Flores S; Keefe S; Chen C; Su Y; McDade EM; Wang G; Li Y; Hassenstab J; Aschenbrenner A; Hornbeck R; Jack CR; Ances BM; Berman SB; Brosch JR; Galasko D; Gauthier S; Lah JJ; Masellis M; van Dyck CH; Mintun MA; Klein G; Ristic S; Cairns NJ; Marcus DS; Xiong C; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
    Brain; 2019 Apr; 142(4):1063-1076. PubMed ID: 30753379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1.
    Laforce RJ; Dallaire-Théroux C; Racine AM; Dent G; Salinas-Valenzuela C; Poulin E; Cayer AM; Bédard-Tremblay D; Rouleau-Bonenfant T; St-Onge F; Schraen-Maschke S; Beauregard JM; Sergeant N; Puymirat J
    J Neurol; 2022 Jul; 269(7):3579-3587. PubMed ID: 35103843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients.
    Choo IL; Carter SF; Schöll ML; Nordberg A
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2120-6. PubMed ID: 25077930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice.
    Button EB; Boyce GK; Wilkinson A; Stukas S; Hayat A; Fan J; Wadsworth BJ; Robert J; Martens KM; Wellington CL
    Alzheimers Res Ther; 2019 May; 11(1):44. PubMed ID: 31084613
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.
    Gulyás B; Pavlova E; Kása P; Gulya K; Bakota L; Várszegi S; Keller E; Horváth MC; Nag S; Hermecz I; Magyar K; Halldin C
    Neurochem Int; 2011 Jan; 58(1):60-8. PubMed ID: 21075154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment.
    Chandra A; Valkimadi PE; Pagano G; Cousins O; Dervenoulas G; Politis M;
    Hum Brain Mapp; 2019 Dec; 40(18):5424-5442. PubMed ID: 31520513
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of positron emission tomography imaging in understanding Alzheimer's disease.
    Barthel H; Seibyl J; Sabri O
    Expert Rev Neurother; 2015 Apr; 15(4):395-406. PubMed ID: 25752209
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography.
    Timmers T; van Berckel BNM; Lammertsma AA; Ossenkoppele R
    Methods Mol Biol; 2018; 1750():221-229. PubMed ID: 29512076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Astrocyte Reactivity in Alzheimer's Disease: Therapeutic Opportunities to Promote Repair.
    Mirzaei N; Davis N; Chau TW; Sastre M
    Curr Alzheimer Res; 2022; 19(1):1-15. PubMed ID: 34719372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.